Detalles de la búsqueda
1.
Peptide nucleic acid-dependent artifact can lead to false-positive triplex gene editing signals.
Proc Natl Acad Sci U S A
; 118(45)2021 11 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34732575
2.
Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation.
Qual Life Res
; 26(7): 1785-1798, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28341926
3.
Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment.
Antimicrob Agents Chemother
; 60(9): 5135-40, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27216057
4.
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Lancet
; 385(9987): 2606-15, 2015 Jun 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-25890673
5.
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
HIV Clin Trials
; 17(2): 78-87, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26892863
6.
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.
HIV Clin Trials
; 15(5): 218-30, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25350960
7.
Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial.
AIDS Res Ther
; 11: 39, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25926858
8.
Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.
J Acquir Immune Defic Syndr
; 74(2): 180-184, 2017 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27673443
9.
A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults.
J Acquir Immune Defic Syndr
; 74(2): 193-200, 2017 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27753684
10.
Current status and prospects of HIV treatment.
Curr Opin Virol
; 18: 50-6, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27023283
11.
Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.
Antiviral Res
; 125: 63-70, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26640223
12.
Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects.
J Acquir Immune Defic Syndr
; 72(3): 281-8, 2016 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26885802
13.
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
J Acquir Immune Defic Syndr
; 73(3): 294-298, 2016 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27171740
14.
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.
EBioMedicine
; 13: 321-327, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27742226
15.
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.
J Acquir Immune Defic Syndr
; 71(5): 530-7, 2016 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26627107
16.
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
J Acquir Immune Defic Syndr
; 72(1): 58-64, 2016 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26829661
17.
Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
J Acquir Immune Defic Syndr
; 67(1): 52-8, 2014 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24872136
18.
Phase IIIb, open-label single-arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV-1-infected treatment-nave adults.
J Int AIDS Soc
; 17(4 Suppl 3): 19772, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25397516
19.
Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope.
J Acquir Immune Defic Syndr
; 62(1): 1-9, 2013 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23023102
20.
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results.
J Acquir Immune Defic Syndr
; 62(5): 483-6, 2013 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23337366